R Fiasse Selected Research

Biomarkers (Surrogate Marker)

9/2004

Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

R Fiasse Research Topics

Disease

3	Crohn Disease (Crohn's Disease) 09/2004 - 06/2002
1	Hypersensitivity (Allergy) 04/2010
1	Urologic Diseases (Urinary Tract Disease) 04/2010
1	Bone Resorption 09/2004
1	Dysentery 07/2003
1	Fistula 07/2002
1	Inflammation (Inflammations) 07/2002
1	Carcinoma (Carcinomatosis) 07/2001
1	Esophageal Neoplasms (Esophageal Cancer) 07/2001
1	Margins of Excision 07/2001
1	Neoplasms (Cancer) 07/2001
1	Polyps 01/2001
1	Neoplasm Metastasis (Metastasis) 01/2001

Drug/Important Bio-Agent (IBA)

3	Infliximab (Remicade)FDA Link 09/2004 - 06/2002
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2002 - 06/2002
2	Phenobarbital (Luminal)FDA Link 07/2002 - 06/2002
1	Biological ProductsIBA 04/2010
1	Procollagen Type IIBA 09/2004
1	collagen type I trimeric cross-linked peptideIBA 09/2004
1	Alkaline PhosphataseIBA 09/2004
1	Biomarkers (Surrogate Marker)IBA 09/2004
1	OsteocalcinIBA 09/2004
1	Collagen Type I (Type I Collagen)IBA 09/2004
1	ORALIT (ORS)IBA 07/2003
1	C-Reactive ProteinIBA 07/2002
1	AntibodiesIBA 06/2002
1	MotilinIBA 01/2001

Therapy/Procedure

1	Therapeutics 09/2004
1	Self Medication 07/2003
1	Esophagectomy 07/2001
1	Hepatectomy 01/2001